SecBot SecBot
PRESS-RELEASE ·Filed Apr 21, 2026

RVMD

Revolution Medicines, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Anticipate significant positive stock movement ahead of the ASCO plenary presentation on May 31, 2026, especially if full data confirms survival benefit and safety profile. This could accelerate FDA approval and position daraxonrasib as a new standard of care in a high-mortality indication with limited options.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$148.90
T+0 close · Apr 21, 2026 · via day close
Latest settled
+20.34%
T+60 · $179.18
Vs SPY
+13.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 21 $148.90entry
  2. T+1 · 7mo ago −4.97%α −5.99% · $141.50
  3. T+5 · 7mo ago −2.73%α −3.82% · $144.83
  4. T+20 · 6mo ago −3.04%α −7.96% · $144.37
  5. T+60 · 4mo ago +20.34%α +13.44% · $179.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines announced that detailed results from its Phase 3 RASolute 302 trial of daraxonrasib in metastatic pancreatic cancer will be presented at ASCO 2026, following previously reported unprecedented overall survival benefit. The drug met all primary and key secondary endpoints, including statistically significant improvements in progression-free and overall survival versus chemotherapy.

Key Facts

  • Daraxonrasib demonstrated statistically significant and clinically meaningful improvement in both PFS and OS vs standard chemotherapy in previously treated metastatic PDAC.
  • Results from the Phase 3 RASolute 302 trial will be presented in a Plenary Session at ASCO 2026, a high-profile venue indicating clinical importance.
  • FDA has granted Breakthrough Therapy and Orphan Drug Designations for daraxonrasib; it is also part of the FDA Commissioner’s National Priority Voucher program.
  • The trial included patients with various RAS mutations (G12D, G12V, G12R) and RAS wild-type, broadening potential applicability.
  • Daraxonrasib is an oral, once-daily RAS(ON) multi-selective inhibitor, offering a convenient alternative to intravenous chemotherapy.

Financial Impact

Potential blockbuster drug with peak sales estimates exceeding $5B annually in metastatic pancreatic cancer alone, based on unmet need and trial results.

revenuemarketCapdilution

Risk Factors

  • Regulatory approval is not guaranteed despite Breakthrough designation; FDA may require additional data.
  • Safety concerns could emerge in full dataset, limiting commercial potential.
  • Competition from other RAS inhibitors in development may affect market share post-approval.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3278211

US Market Status

Market Closed · Opens in 9h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026